CLDN6-Targeted CAR Shows Some Signs of Activity in Solid Tumors
CARVac RNA vaccine may amplify the persistence of the BNT211 CAR T-cell therapy.
Benjamin L. Schlechter, MD, on TAC01-HER2 in HER2-Positive Solid Tumors
Schlechter discussed the potential advantages of TAC01-HER2 over current standards of care.
Benjamin L. Schlechter, MD, on Addressing Unmet Needs in HER2 Positive Solid Tumors
Schlechter discussed the design of the TACTIC-2 clinical trial for patients with HER2-positive solid tumors.
Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies
The chief medical officer of Triumvira Immunologics discussed the company’s future plans.
Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.
Jeffrey Miller, MD, on Emerging Research With Natural Killer Cells
The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.
Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors
The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.
David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid Tumors
Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer
Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
IL13Rα2 Universal CAR T Therapy Shows Antitumor Activity in Recurrent Glioma
MT026 had an overall response rate of 83.3% in a first-in-human, investigator-initiated trial.
SNK01/Checkpoint Inhibitor Combo Yields Sustained Remission in Advanced SRC Sarcoma Case
The FDA authorized the natural killer cell therapy combo for compassionate use.
Phase 1 Clinical Trial Will Assess CAR-T With Genetic and Epigenetic Reprogramming for Solid Tumors
Improved functional activity compared to ROR-1-targeted CAR-T therapies without the 2 forms of reprogramming was demonstrated in preclinical studies.
Oncolytic Virus T-VEC Demonstrates Long-Term Benefits in Melanoma
The 5-year relapse-free survival rate was 22.3% with T-VEC prior to surgery, compared with 15.2% for surgery alone.
EpCAM-Targeted CAR-T Therapy Shows Promise in Colorectal, Gastric Cancer
Of the 8 treated patients who were evaluable, 6 patients had stable disease at Day 28.
TIL Therapy Superior to Ipilimumab for Progression-Free Survival in Unresectable Melanoma
Based on the findings, investigators are considering registration with the FDA and EMA.
TCR T-Cell Therapy Shows Efficacy Across MAGE-A4+ Solid Tumors
ADP-A2M4CD8 will be evaluated in the phase 2 SURPASS-3 trial initiating in late 2022 or early 2023.
DdBCMA-Targeted CAR-T Therapy Shows Clinical Activity in Multiple Myeloma
Among the 31 patients evaluable for efficacy analysis, ORR was 100%.
PD1 Knockout CAR T-Cell Therapy Well-Tolerated, Yields Durable Response in DLBCL
A phase 2 trial evaluated the therapy in patients with diffuse large B-cell lymphoma, B-acute lymphocytic leukemia, and follicular lymphoma.
CAR T/CARVac Therapy Yields Responses in Refractory Testicular Cancer
BNT211 showed encouraging responses in testicular cancer but less encouraging responses in ovarian cancer.
Natural Killer Cell Therapy Well Tolerated in Solid Tumors
Thorsten Graef, MD, PhD, chief medical officer, Acepodia, discussed data on ACE1702 presented at ESMO 2021.
2 Clarke Drive Cranbury, NJ 08512